Background Minimal Change Disease (MCD) in relapse is associated with increased podocyte CD80 expression and elevated urinary CD80 excretion, whereas focal segmental glomerulosclerosis (FSGS) has mild or absent CD80 podocyte expression and normal urinary CD80 excretion. Methods One patient with MCD, one patient with primary FSGS and three patients with recurrent FSGS after transplantation received CD80 blocking antibodies (abatacept or belatacept). Urinary CD80 and CTLA-4 levels were measured by ELISA. Glomeruli were stained for CD80. Results After abatacept therapy, urinary CD80 became undetectable with a concomitant transient resolution of proteinuria in the MCD patient. In contrast, proteinuria remained unchanged after abatacept or belatacept therapy in the one patient with primary FSGS and in two of the three patients with recurrent FSGS despite the presence of mild CD80 glomerular expression but normal urinary CD80 excretion. The third patient with recurrent FSGS after transplantation had elevated urinary CD80 excretion immediately after surgery which fell spontaneously before the initiation of abatacept therapy; after abatacept therapy, his proteinuria remained unchanged for 5 days despite normal urinary CD80 excretion. Conclusion These observations are consistent with a role of podocyte CD80 in the development of proteinuria in MCD. In contrast, CD80 may not play a role in recurrent FSGS since the urinary CD80 of our three patients with recurrent FSGS was only increased transiently after surgery and normalization of urinary CD80 did not result in resolution of proteinuria.
Introduction
There are three major variants of idiopathic nephrotic syndrome based on histological pattern: minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS) and mesangial proliferative glomerulonephritis [1] . In contrast to patients with idiopathic FSGS, patients with MCD present with nephrotic syndrome at an earlier age, usually respond to corticosteroids and have an excellent long-term prognosis [2] . Despite these clinical differences, it is still a matter of debate whether MCD and FSGS are two different entities or rather represent a continuum of the same disease at different stages. Indeed, histopathologic diagnosis is not always definitive since podocyte foot process effacement may be the only histological finding in the early stage of FSGS [3] .
B o t h M C D a n d F S G S a r e c o n s i d e r e d t o b e podocytopathies [4] . In previous publications, our group reported the expression of de novo CD80 in podocytes of MCD patients during relapse which was associated with increased shedding of intact CD80 molecules into the urine [5, 6] . The potential causal role for CD80 in the proteinuria is suggested by the fact that lipopolysaccharide (LPS)-induced proteinuria is also associated with podocyte CD80 expression and that proteinuria in this model is prevented in mice lacking fulllength CD80 [7] .
Patients with primary FSGS have urinary CD80 levels which are no different from those observed in control subjects despite the former presenting with massive proteinuria, suggesting that the presumed mechanism of proteinuria in primary FSGS is not CD80-driven [6] but rather mediated by a circulating factor [8] . While preliminary studies suggest a role of cardiotrophin-like cytokine-1 [9] , the most intensely studied candidate for FSGS is circulating soluble urokinase type plasminogen activator receptor, which triggers podocyte integrin activation and proteinuria [10] [11] [12] .
CTLA-4, a CD80 inhibitor, is known to be expressed in cultured human podocytes exposed to Poly:IC, a toll-like receptor ligand [13] . Nevertheless, we found no significant differences in urinary excretion of CTLA-4 in MCD patients during relapse compared to that observed during remission [5] . We have therefore hypothesized that if CTLA-4 is involved in MCD, regulation may be at the local level and involve inadequate censoring of podocyte CD80 expression due to an impaired production of CTLA-4 by podocytes [14] . Thus, if MCD represents a defect in the autoregulatory CD80/ CTLA-4 axis in the podocyte, one might predict that the administration of CTLA-4 (CTLA4-IgG1) to a subject with MCD would result in an inhibition of podocyte and urinary CD80 with the resolution of proteinuria, whereas the administration of CTLA-4-IgG1 infusion to FSGS patients would not be beneficial as in this condition CD80 is likely not involved in the pathogenesis of the proteinuria.
Here we present our experience with the CD80-blocking antibodies abatacept or belatacept in one patient with relapsing MCD, one patient with primary FSGS and three patients with recurrence of FSGS after kidney transplantation.
Methods
This study was performed in accordance with the Declaration of Helsinki and the Declaration of Istanbul and was approved by the Institutional Review Board of the University of Florida and The Johns Hopkins University. Written informed consent was obtained from each patient before participation. The Institutional Review Board provided approval for this study before abatacept and belatacept were infused.
Patient selection Minimal Change disease and FSGS were defined by renal biopsy according to criteria established by the International Study for Kidney Diseases in Children [15] . One patient with MCD and four patients with primary FSGS were included in this study. Three of the latter patients were studied after recurrence of the nephrotic syndrome in the transplanted kidney. Recurrence after transplantation was defined based on the presence of nephrotic syndrome and podocyte foot process effacement in the kidney biopsy.
Urinary CD80 and CTLA-4 measurements Urinary CD80 was measured by an enzyme-linked immunosorbent assay (ELISA) using a commercially available kit (eBioscience, San Diego, CA). We measured urinary CTLA-4 according to the method of Oaks and Hallet with minor modifications [16] . CD80 and CTLA-4 results were adjusted for urinary creatinine excretion.
Urinary protein-to-creatinine ratio Urine protein was calculated using the BioRad Protein Assay (BioRad, Hercules, CA) and urine creatinine with the Creatinine Companion (Exocell, Philadelphia, PA).
Immunohistochemistry
Frozen biopsy slides were equilibrated to room temperature, and water precipitation was absorbed carefully. Slides were fixed in 95 % ethanol for 10 min. Sections were washed with phosphate-buffered saline (PBS). Unspecific sites were blocked for 30 min with normal goat and donkey 5 % serum/PBS. Sections were incubated with monoclonal synaptopodin antibody (1:1) for 1 h at room temperature to reveal podocytes. After being washed three times with PBS (3 min each wash), the slides were incubated with anti-B7-1 antibody (1:100) (goat; R&D Systems, Minneapolis, MN) for 1 h at room temperature, then washed three times with PBS (3 min each wash), followed by incubation with chicken antigoat 488 and chicken anti-mouse 594 Alexa Fluor antibodies (1:1500, Invitrogen, Carlsbad, CA) for 1 h at room temperature. Following three washes in PBS (3 min each wash), sections were incubated with DAPI/PBS solution for 5 min and then washed with PBS and water.
A negative control is shown in Fig. 1 .
Results
Demographics, immunosuppressive therapy, renal histology and laboratory tests are shown in Table 1 . Serial measurements of the urine protein-to-creatinine (UPC) ratio, urinary CD80 and urinary CTLA-4 excretion of patients 1-5 are represented in Figs. 2, 3, 4, 5 and 6, respectively.
Patient 1 (MCD)
Patient 1 presented with steroid-sensitive nephrotic syndrome at the age of 2 years. Subsequently, he suffered two relapses within 5 months. The first relapse occurred within 2 weeks after the completion of prednisone tapering, and the second one occurred during prednisone tapering, a pattern consistent with steroid dependence. A kidney biopsy confirmed MCD as the underlying pathology. At this time tacrolimus was added to his therapy. However, he experienced repeat relapses triggered by upper respiratory infections. After discussion with his family, the decision to give abatacept was made. Prednisone was tapered from 30 to 15 mg/day 3 days prior to the administration of abatacept and then from 15 to 6 mg/day 3 days thereafter. The administration of abatacept was associated with a dramatic fall in urinary CD80 excretion to an undetectable range within 24 h. This finding was followed by a drop in the UPC ratio within 72 h after the administration of abatacept, reaching a nadir of 0.03 eight days later (Fig. 2) . Unfortunately, the remission was short, and 11 days after abatacept administration, the UPC ratio had risen to 2.68 and the urinary CD80 excretion had risen to 146 (ng/g creatinine). Two days later (day 13), prednisone was tapered to 3 mg/day, tacrolimus was discontinued and a second dose of abatacept was given. Urinary CD80 excretion normalized within 24 h of the second dose, and the UPC ratio decreased to 0.72 fifteen days after the second abatacept infusion; once again, however, proteinuria and urinary CD80 excretion increased 2 days later, although at a lower level than observed previous to the second abatacept infusion.
Patient 2 (primary FSGS)
Patient 2 received abatacept during relapse at a time when the urinary CD80 excretion was within the normal range despite the presence of nephrotic-range proteinuria and mild anasarca. Abatacept infusion was not associated with any improvement in proteinuria (Fig. 3 ). Urinary CD80 excretion rose to 258 ng/ g creatinine 16 days after abatacept therapy but normalized 4 days later with no changes in immunosuppression. Since the patient remained in relapse, a second dose of abatacept was given. At that time, urinary CD80 was again within the normal range and became undetectable within 24 h after the abatacept infusion. However, the UPC ratio remained unchanged in the nephrotic range.
Patient 3 (recurrent FSGS)
Patient 3 received abatacept because of recurrence of FSGS after kidney transplantation. Urinary CD80 excretion was elevated (614 ng/g creatinine) immediately after surgery, subsequently decreasing to 281 ng/g creatinine prior to the abatacept infusion and plasmapheresis on post-surgery day 6 (Fig. 4) . The UPC ratio remained elevated during the next 6 days after abatacept, despite a marked fall in urinary CD80 excretion to the normal range (54 ng/g creatinine). The patient achieved partial remission 11 days after plasmapheresis, abatacept and cyclophosphamide therapy were initiated.
Patient 4 (recurrent FSGS)
Patient 4 experienced FSGS recurrence immediately after kidney transplantation. Nephrotic syndrome did not respond to plasmapheresis and rituximab. Given the persistence of proteinuria, abatacept was administered despite urinary CD80 excretion being within the normal range (9.8 g/ng creatinine) at the time of abatacept administration and for the following 3 weeks (Fig. 5 ). During the same period of time, proteinuria remained within the nephrotic range. A second dose of abatacept was given without any improvement in proteinuria.
Patient 5 (recurrent FSGS)
Patient 5 experienced FSGS recurrence 9 days following deceased-donor kidney transplantation. She had nephrotic range proteinuria, and her index biopsy showed diffuse podocyte foot process effacement and marked staining of CD80. After 16 plasmapheresis sessions and four doses of rituximab she continued to have proteinuria within the nephrotic range. She was initiated on repeat belatacept infusion (16 doses). This therapy, however, did not result in any improvement in the proteinuria despite the presence of normal urinary CD80 levels (Fig. 6 ).
Discussion
The results of our study suggest that the underlying mechanism leading to proteinuria may differ in MCD and FSGS. Thus, the relationship of CD80/CTLA-4 seems to be crucial in the development of proteinuria in MCD, whereas it does not appear to play a role in FSGS. Consistent with our previous studies [5, 6] , the MCD patient (patient 1) showed a high urinary CD80 excretion along with low urinary CTLA-4 excretion at the time of relapse. We hypothesized that MCD might be responsive to CTLA-4 therapy, based on the hypothesis that CTLA-4 could inhibit the increased CD80 podocyte expression seen in these patients. Indeed, in vitro, CTLA4-Ig binds to CD80 on podocytes leading to internalization of the CD80-CTLA4 complex [17] . We therefore administered abatacept (CTLA-4-IgG1), which is a fusion protein that comprises the extracellular domain of human CTLA-4 and an Fc fragment of human immunoglobulin G subclass 1 (IgG1) [18] . The administration of abatacept resulted in a marked rise in urinary CTLA-4 concomitant with a dramatic plummeting of urinary CD80 excretion at 24 h, followed by the resolution of proteinuria within 7 days. Nevertheless, increasing proteinuria was observed beginning on day 9, associated with increased urinary CD80 urinary levels. A second dose of abatacept resulted in the same findings, with a marked initial reduction in urinary CD80 within 24 h associated with a progressive fall in urinary protein excretion, again followed by increasing urinary protein excretion a few days later, yet at a lower level than that seen prior to abatacept therapy. The acute reduction of proteinuria is likely due to the abatacept since:(1) proteinuria persisted while the patient was on higher doses of prednisone and tacrolimus, but remitted within hours after abatacept was administered, (2) we observed the same pattern of changes in CTLA-4, CD80 and urinary protein excretion after the second abatacept administration, despite the fact that the patient was only receiving 0.2 mg/kg/day prednisone and (3) the reduction in proteinuria was preceded by a marked reduction in urinary CD80 excretion. Our results do not rule out, however, the possibility that the prednisone therapy with or without tacrolimus may have had a contributory role in the response, especially after the first abatacept infusion.
These observations provide clinical evidence that there is a dysregulation of the CD80-CTLA-4 axis in MCD, as suggested in a recent publication [19] . Indeed, many single nucleotide polymorphisms have been identified for the CTLA-4 gene [20, 21] . The +49GG genotype has been associated with decreased expression of CTLA-4, and the frequency of this genotype has been found significantly increased in MCD patients compared to normal controls [20] .
The remarkable and dramatic fall in urinary CD80 after the administration of abatacept followed by the resolution of proteinuria provides evidence that abnormalities in podocyte CD80 may likely play a role in the pathogenesis of MCD. CTLA4-IgG1 may be of clinical significance in those patients with severe steroid dependency and steroid resistance with elevated urinary CD80 excretion. However, this approach must be tempered by the fact that the effect of CTLA4-IgG1 lasted only a few days.
In contrast to MCD, the mechanism of proteinuria in FSGS seems unlikely to be CD80-driven. In support of this statement, we previously reported that urinary CD80 excretion in patients with FSGS was similar to that observed in healthy controls and lower than that seen in MCD patients in relapse [5, 6] . This finding has been confirmed by others (Segarra et al., personal communication). In the case series of the present study, patient 3 with recurrent FSGS had elevated levels of urinary CD80 immediately after transplantation, which is in contrast to what has been observed in primary FSGS. However, urinary CD80 excretion fell spontaneously before the administration of abatacept. Urinary CD80 reached a nadir of 54 ng/g creatinine (within the normal range) within 24 h after the administration of abatacept. Despite the presence of normal urinary CD80 excretion, proteinuria remained unchanged for 5 days. Chang et al. recently found that cultured podocytes exposed to hypoxia showed an increased expression of CD80 and the hypoxia-inducible-factor (HIF), resulting in changes in cytoskeletal rearrangement [22] . In this study, CD80 glomerular expression was upregulated to a similar magnitude as observed in the LPS model of proteinuria. Thus, it could be hypothesized that the increased urinary CD80 observed in our patient 3 may have been the consequence of a non-specific response of the podocyte to ischemia occurring during the transplantation procedure, as opposed to being in response to a circulating factor in FSGS. In agreement with this notion, patients 4 and 5 showed normal excretion of urinary CD80 despite recurrence of FSGS with persistent nephrotic syndrome. Patients 4 and 5 underwent kidney transplantation 10 and 12 weeks, respectively, prior to monitoring of urinary CD80 and administration of CTLA4-IgG1. In addition, the administration of CTLA4-IgG1 did not result in any change in proteinuria.
Yu et al. recently reported partial or complete remission using abatacept in four patients with recurrent FSGS after transplantation and in one patient with primary FSGS [23] . These authors considered this therapy after they found positive CD80 staining in the biopsies of these patients. However, there are some concerns with their interpretation of these results. First, the authors suggest that achievement of the clinical response was due to abatacept therapy. However, previous publications have shown a similar rate and timing of remission in patients with FSGS recurrence who did not receive abatacept, especially when plasmapheresis was part of the therapy (Table 2 ) [24] [25] [26] . Second, the absence of urinary CD80 measurements prior to and after kidney transplantation makes the significance of the CD80 immunostaining immediately after transplantation uncertain. Indeed, we have previously found minimal CD80 segmental glomerular staining in one primary FSGS patient, but her urinary CD80 level (75 ng/g creatinine) was similar to that seen in controls [6] . Furthermore, in the study by Yu et al., the two transplanted patients who had positive CD80 staining underwent biopsy within 2 h post-reperfusion. It remains possible that the increased CD80 expression observed in the glomeruli might have been the result of hypoxia-induced injury to the podocyte. Finally, the authors included a patient with native FSGS who also had positive CD80 staining in the kidney biopsy. The fact that this patient had a normal glomerular filtration rate 20 years after first being diagnosed with FSGS highly suggests MCD as the underlying disease rather than FSGS. In response to the Yu et al. paper [23] , Alachkar et al. [27] presented data of five patients with biopsy-proven FSGS after transplantation who did not respond to plasmapheresis and rituximab and who subsequently received CD80 blockers, i.e. abatacept or the even stronger CD80 blocking agent belatacept. The patients did not show any therapeutic responses, despite positive podocyte CD80 expression in their respective kidney biopsy specimens. In another response to the Yu In summary, this small case series suggests differences in clinical responses to CTLA4-IgG1 in subjects with MCD and recurrent FSGS. The rapid though transient resolution of proteinuria with urinary CD80 excretion in the subject with MCD is consistent with the mechanism of proteinuria being mediated by a dysregulation of the CD80-CTLA-4 axis. The transient nature of the defect makes the administration of CTLA4-IgG1 impractical to treat these patients. Other modalities controlling CD80 excess production need to be considered. In contrast, our studies and previous studies [27] suggest that the response of recurrent FSGS to CTLA4-IgG1 is poor and suggests that this disease is not mediated by dysregulated expression of CD80. Although CD80 glomerular expression in post-transplant FSGS may be increased immediately after surgery, this may be due to hypoxia, and the increased urinary CD80 excretion is transitory and does not appear to be modulated by CTLA-4 Ig therapy.
Our results and those of a previous study [27] show no benefit in using CD80-blockade in nine patients with FSGS and thus stand in sharp contrast to those results observed by Yu et al. who analyzed five patients [23] . Before the use of anti-CD80 therapy becomes a popular consideration in patients with primary FSGS, we recommend that well-designed control studies be conducted to resolve this issue of target engagement, effectiveness and safety of CD80 blockade using abatacept or belatacept.
